TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05033249

Intervention type: DIAGNOSTIC_TEST
Intervention: Immature granulocyte count
Description: Automatically calculated immature granulocyte count in white blood cell count

Intervention type: DIAGNOSTIC_TEST
Intervention: Immature granulocyte count
Description: Automatically calculated immature granulocyte count in white blood cell count

Intervention type: DIAGNOSTIC_TEST
Intervention: Immature granulocyte percentage
Description: Automatically calculated immature granulocyte percentage in white blood cell count

Intervention type: DIAGNOSTIC_TEST
Intervention: Immature granulocyte percentage
Description: Automatically calculated immature granulocyte percentage in white blood cell count
Study: NCT02872805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEPFAR Enhanced Standard of Care (PESCA)
Description: Standardized materials will be provided to PEPFAR supported clinical sites to assist clinic teams with supporting patients in the transition from pediatric to adult medical care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Transition Advocate (PTA)
Description: The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
Study: NCT02134093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium
Description: Anesthesia induction:midazolam (0.03\~0.05 mg/kg), sufentanil(0. 5\~0.8 μg/kg), etomidate ( 0.2\~0.6mg/kg) and rocuronium(0.6mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium
Description: Anesthesia induction:midazolam (0.03\~0.05 mg/kg), sufentanil(0. 5\~0.8 μg/kg), etomidate ( 0.2\~0.6mg/kg) and rocuronium(0.6mg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium
Description: Anesthesia induction:midazolam (0.03\~0.05 mg/kg), sufentanil(0. 5\~0.8 μg/kg), etomidate ( 0.2\~0.6mg/kg) and rocuronium(0.6mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Continuous pump infusion dexmedetomidine at 0.5μg/kg （low dose group）or 1μg/kg （high dose group）for 15 minutes before anesthesia induction，then followed by a continuous pump infusion at 0.2 μg/kg/h（low dose group）or 0.4μg/kg/h（high dose group） until the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Continuous pump infusion dexmedetomidine at 0.5μg/kg （low dose group）or 1μg/kg （high dose group）for 15 minutes before anesthesia induction，then followed by a continuous pump infusion at 0.2 μg/kg/h（low dose group）or 0.4μg/kg/h（high dose group） until the end of surgery.
Study: NCT04663412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node mapping with indocyanine green fluorescence imaging in vulvar cancer (FIGO Stage IB)
Description: Patients diagnosed with vulvar squamous cell carcinoma (FIGO IB stage) underwent bilateral radical vulvectomy, SLN search and removal, and bilateral inguinal lymphadenectomy at the Cannizzaro Hospital Operative Unit of Obstetrics and Gynecology Department (Catania, Italy). 3 ml of indocyanine green (ICG) 0.5 mg/mL was administered in 3 peritumoral injections under general anesthesia to screen the SLN. The images were acquired using an intraoperative infrared camera system, which allowed intraoperative visualization of the SLN. An SLN was identified for each patient. The lymph nodes examined by the pathologist were negative for metastatic localization of the disease. However, patients underwent bilateral inguinofemoral lymphadenectomy, as this procedure is not currently codified as a gold standard for the detection of SLN in vulvar cancer.
Study: NCT00770705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine
Description: The drug will be administered in the operating room. After induction of anesthesia and the pIacement of appropriate cardiovascular monitoring lines, an initial loading dose of 0.25 mg/kg will be administered intravenously immediately prior to cardiopulmonary bypass.For up to 72 hours postoperatively, 0.25 mg/kg/day will be administered Based on published pharmacokinetic data these doses should block 90 -95% of alpha-peripheral receptors with a half life of 24 - 36 hours for regeneration.
Study: NCT02134093

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Continuous pump infusion normal saline with identical volume of dexmedetomidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance of anesthesia , propofol, remifentanil,vecuronium
Description: Continuous infusion of propofol （3\~6 mg/kg/h）, remifentanil （0.05\~0.3 μg/kg/min）is required to maintain Entropy within 40\~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05\~0.1mg/kg） as needed to maintain muscle relaxation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance of anesthesia , propofol, remifentanil,vecuronium
Description: Continuous infusion of propofol （3\~6 mg/kg/h）, remifentanil （0.05\~0.3 μg/kg/min）is required to maintain Entropy within 40\~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05\~0.1mg/kg） as needed to maintain muscle relaxation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maintenance of anesthesia , propofol, remifentanil,vecuronium
Description: Continuous infusion of propofol （3\~6 mg/kg/h）, remifentanil （0.05\~0.3 μg/kg/min）is required to maintain Entropy within 40\~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05\~0.1mg/kg） as needed to maintain muscle relaxation.
Study: NCT01877200

Intervention type: OTHER
Intervention: No treatment given
Description: Patients will fill out a questionnaire by interview.
Study: NCT01845779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCF regimen
Study: NCT04361084

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional simulated training
Description: traditional simulation using actors as standardised patients playing out scenarios plus pre and post questionnaires and semi structured interviews

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed reality simulation
Description: using immersive technologies to create a virtual reality simulated training scenario's plus pre an post questionnaires and semi structured interview's
Study: NCT01439113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided IV placement
Description: The nurse will use the emergency department's ultrasound machine to locate peripheral veins and then cannulate the vessel under ultrasound guidance.
Study: NCT03003234

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Duodenogastroscopy
Description: Catheter goes through the mouth in the duodenum to take duodenal biopsies.

Intervention type: DEVICE
Group type: OTHER
Intervention: Duodenal aspiration catheter
Description: Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutri drink
Description: Liquid meal of 200 ml.
Study: NCT02605759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoBalloon Focal Ablation System
Description: Positioned within the esophagus at the target location, the Balloon is simultaneously inflated and cooled with nitrous oxide. The nitrous oxide cools the inner Balloon surface. The Balloon remains stationary during the delivery of the nitrous oxide for the Cryoablation of Dysplastic Squamous Tissue in Patients with Esophageal Squamous Cell Dysplasia
Study: NCT00750763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colonlytely
Description: Bowel preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picolax/Picoprep
Description: Bowel preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fleet
Description: Bowel preparation
Study: NCT01983215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena vac
Study: NCT00698815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT00555074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Tungstate
Description: Sodium Tungstate, 200 mg BID, oral route during 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, BID, oral route during 6 weeks
Study: NCT04726735

Intervention type: BIOLOGICAL
Intervention: Samples of bladder tissue
Description: Samples of bladder tissue collected between 2007 and 2011.

Intervention type: BIOLOGICAL
Intervention: Samples of bladder tissue
Description: Samples of bladder tissue collected between 2007 and 2011.

Intervention type: BIOLOGICAL
Intervention: Samples of bladder tissue
Description: Samples of bladder tissue collected between 2007 and 2011.
Study: NCT04197271

Intervention type: PROCEDURE
Intervention: Emergency Hernia Repair
Description: Emergency repair of hernia using method selected by treating surgeon.

Intervention type: OTHER
Intervention: Conservative management
Description: Treatment of hernia without resort to surgery
Study: NCT03901846

Intervention type: DEVICE
Group type: OTHER
Intervention: ColdZyme
Description: ColdZyme is a Class I medical device (CE-marked) with the following composition: glycerol, water, Tris buffer, CaCl2, menthol and trypsin
Study: NCT02307227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT03490617

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal misoprostol
Description: To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal misoprostol
Description: To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women
Study: NCT03940872

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-questionnaire 3PDQ
Description: Visit 1 : - The patient will have to complete the 3PDQ self-questionnaire. - The investigator will conduct an interrogation and a neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visit 2 : - The patient will have to complete the 3PDQ self-questionnaire.~- An investigator, obligatorily different from the investigator of the visit 1, will conduct to the same interrogation and the same neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visits 1 and 2 can be made on the same day. In this case the patient will fill the 3PDQ self questionnaire only once.
Study: NCT02314728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.
Study: NCT04822714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Career Competencies Intervention
Description: Mobile career competencies intervention aim to enhance the career competencies (career behavioral action) among the participants
Study: NCT03949595

Intervention type: OTHER
Intervention: Data collection
Study: NCT03035513

Intervention type: OTHER
Intervention: Continuous spikes and waves during slow sleep (CSWS)

Intervention type: OTHER
Intervention: Continuous spikes and waves during slow sleep (CSWS)
Study: NCT00542893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genasense® (G3139, oblimersen sodium)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genasense® (G3139, oblimersen sodium)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genasense followed by DTIC; then DTIC alone
Description: Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC alone; then Genasense followed by DTIC
Description: Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
Study: NCT03423043

Intervention type: RADIATION
Intervention: Low Dose CT Scan of the Wrist
Description: A low dose CT scan will be obtained in patients with a distal radius fracture of the wrist.
Study: NCT00764790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Study: NCT00971477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Teledermatology Care
Description: Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional in Office Care
Description: Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
Study: NCT03041636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study: NCT02987296

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immunonutrition with arginine
Description: Nutritional beverage containing supplemental arginine taken 3 times per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Immunonutrition without Arginine
Description: Nutritional beverage without supplemental arginine taken 3 times per day
Study: NCT00445471

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mifne Approach to PDD

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Study: NCT03539978

Intervention type: OTHER
Intervention: SM-THINk
Description: Patients will receive the SM-THINk enhanced discharge method.
Study: NCT00770705

Intervention type: OTHER
Group type: OTHER
Intervention: Standard surgical approach
Description: Historical controls
Study: NCT04465799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENTREN
Description: ENTREN intervention for children (cognitive-behavioral perspective + motivational interview)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENTREN-F
Description: ENTREN intervention for children + family intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: Behavioral modification of habits
Study: NCT02143011

Intervention type: OTHER
Group type: OTHER
Intervention: orange juice
Description: intervention assigned: 2-week consumption of naturally-sweetened orange juice providing 25% of energy requirement

Intervention type: OTHER
Group type: OTHER
Intervention: orange juice
Description: intervention assigned: 2-week consumption of naturally-sweetened orange juice providing 25% of energy requirement

Intervention type: OTHER
Group type: OTHER
Intervention: sucrose
Description: intervention assigned: 2-week consumption of sucrose-sweetened beverage providing 25% of energy requirement

Intervention type: OTHER
Group type: OTHER
Intervention: sucrose
Description: intervention assigned: 2-week consumption of sucrose-sweetened beverage providing 25% of energy requirement
Study: NCT05717894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitex Agnus Castus Extract
Description: The patient group received two pills containing 200mg of VAC daily for six months
Study: NCT06043258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bond Apatite
Description: composite graft formed of biphasic calcium sulphate and hydroxyapatite at a ratio of 2:1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss
Description: xenograft bone substitute
Study: NCT03429803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAY101
Description: 28 day cycle, oral, once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAY101
Description: 28 day cycle, oral, once per week
Study: NCT03637218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study: NCT03729375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10cc injection of bupivacaine
Description: 10cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20cc injection of bupivacaine
Description: 20cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
Study: NCT04506645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5381
Description: Single dose REGN5381 administered via IV infusion
Study: NCT01096953

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental health care implemented by telepsychiatry
Description: Care of 6-17 year-olds with ADHD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face care
Description: Psychiatry provided for treatment of ADHD face-to-face in office

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face care
Description: Psychiatry provided for treatment of ADHD face-to-face in office
Study: NCT04506645

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo matching single dose REGN 5381 administered via IV infusion
Study: NCT01182441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN Device
Description: WATCHMAN Left Atrial Appendage Closure Technology

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
Study: NCT04790656

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Subjects will randomly placed into intervention group and control group . In addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform physical exercise on a cycle ergometer with CPAP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer combine with CPAP
Description: Physical exercise on a cycle ergometer combine with CPAP will be performed in a single daily session from the second to the fourth postoperative days . The maximum exercise time for postoperative day 2 will be 20 min, and 30 min for the third and fourth postoperative days.
Study: NCT00384774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered as intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as intravenous infusion
Study: NCT03079453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The patients in Group 1 were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly before tonsillectomy
Study: NCT05931029

Intervention type: DRUG
Intervention: Idebenone
Description: The control group took Idebenone orally for 12 weeks.

Intervention type: DRUG
Intervention: Naohuan Dan and Idebenone
Description: The treatment group took Naohuan Dan combined with Idebenone for treatment. Naohuan Dan is a granular preparation taken once a day, while Idebenone is a tablet taken three times a day for a total of 12 weeks.
Study: NCT01891175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective caesarean section under spinal anaesthesia.
Description: Patients with scheduled caesarean.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective caesarean section under spinal anaesthesia.
Study: NCT04717453

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT02823197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active transport lesson

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active transport lesson and Facebook group